Yi An, MD
Cards
About
Research
Publications
2024
Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells
Lee D, Huntoon K, Wang Y, Kang M, Lu Y, Jeong S, Link T, Gallup T, Qie Y, Li X, Dong S, Schrank B, Grippin A, Antony A, Ha J, Chang M, An Y, Wang L, Jiang D, Li J, Koong A, Tainer J, Jiang W, Kim B. Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nature Biomedical Engineering 2024, 8: 593-610. PMID: 38641710, PMCID: PMC11162332, DOI: 10.1038/s41551-024-01194-7.Peer-Reviewed Original ResearchAntigen-presenting cellsInnate immune pathwaysImmune pathwaysPriming of effector T cellsImmune checkpoint inhibitorsAntitumour immune responseEffector T cellsIntracellular DNA-sensing pathwaysMetastatic breast cancerSyngeneic mouse modelMultiple innate immune pathwaysAdaptive immunogenicityAntitumour responseCheckpoint inhibitorsEndoplasmic reticulum stressT cellsSystemic clearanceBreast cancerDNA-sensing pathwayRelease of mitochondrial DNATherapeutic advantageMouse modelImmune responseEfficient primingIntracellular deliveryPatient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).
Hoffman K, Nguyen P, Rathkopf D, Zurita A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, McKay R, Rose B, Shin K, Kibel A, Taplin M, Kollmeier M. Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP). Journal Of Clinical Oncology 2024, 42: 260-260. DOI: 10.1200/jco.2024.42.4_suppl.260.Peer-Reviewed Original ResearchAbiraterone acetate plus prednisoneSaint Louis University Mental Status ExamMonths of GnRH agonistPatient-reported health-related quality of lifeEPIC-26Radical prostatectomyHealth-related quality of lifeGnRH agonistTreatment armsHormonal functionPROMIS FatigueTreatment to 1 yearQuality of lifeAcetate plus prednisoneMental statusMetastasis-free survivalBaseline to endMental status examStandardized T scoresMild neurocognitive disorderCompletion of treatmentSalvage radiationSalvage radiotherapyOncological outcomesClinically meaningful differences
2023
FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP)
Nguyen P, Kollmeier M, Rathkopf D, Hoffman K, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Shin K, Kibel A, Taplin M. FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP). International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s81-s82. DOI: 10.1016/j.ijrobp.2023.06.401.Peer-Reviewed Original ResearchPSA progression-free survivalMetastasis-free survivalMonths of GnRH agonistAbiraterone acetate/prednisoneSalvage radiotherapyGnRH agonistPre-planned analysisPost-RPStratification factorsProgression-free survivalPost-radical prostatectomyMedian follow-upSubgroup of patientsMulticenter randomized trialOne-sided type I errorPre-planned subgroup analysisStatistically significant benefitTwo-sided p-valuePelvic nodesOpen-labelPrimary endpointSecondary endpointsInvestigator-initiatedSafety profileAdverse eventsFORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).
Nguyen P, Kollmeier M, Rathkopf D, Hoffman K, Zurita A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, McKay R, Rose B, Shin K, Kibel A, Taplin M. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). Journal Of Clinical Oncology 2023, 41: 303-303. DOI: 10.1200/jco.2023.41.6_suppl.303.Peer-Reviewed Original ResearchPSA progression-free survivalMetastasis-free survivalMonths of GnRH agonistAbiraterone acetate/prednisoneSalvage radiotherapyPre-planned analysisGnRH agonistPost-RPStratification factorsProgression-free survivalPost-radical prostatectomyMedian follow-upMonths of ADTSubgroup of patientsMulticenter randomized trialOne-sided type I errorPre-planned subgroup analysisStatistically significant benefitPelvic nodesOpen-labelPrimary endpointSecondary endpointsInvestigator-initiatedSafety profileAdverse events
2022
Downregulation of Sirt6 by CD38 promotes cell senescence and aging
Zhou H, Liu S, Zhang N, Fang K, Zong J, An Y, Chang X. Downregulation of Sirt6 by CD38 promotes cell senescence and aging. Aging 2022, 14: 9730-9757. PMID: 36490326, PMCID: PMC9792202, DOI: 10.18632/aging.204425.Peer-Reviewed Original ResearchConceptsCD38 expressionSIRT6 expressionC3GCD38 siRNACell senescenceIncreased SIRT6 expressionMechanism of CD38H9c2 cellsInduced to senescenceTelomerase reverse transcriptase levelsReverse transcriptase levelsNK cell levelsPresence of C3GNicotinamide adenine dinucleotidePromote cell senescenceReduced reactive oxygen speciesTNF-a levelsDecreased SIRT6 expressionReactive oxygen speciesD-gal induced senescenceHexokinase 2OSS-128167Myocardial H9c2 cellsStimulate cell proliferationSiRNAAssociation of circulating markers with cognitive decline after radiation therapy for brain metastasis.
Huntoon K, Anderson S, Ballman K, Twohy E, Dooley K, Jiang W, An Y, Li J, von Roemeling C, Qie Y, Ross O, Cerhan J, Whitton A, Greenspoon J, Parney I, Ashman J, Bahary J, Hadjipanayis C, Urbanic J, Farace E, Khuntia D, Laack N, Brown P, Roberge D, Kim B. Association of circulating markers with cognitive decline after radiation therapy for brain metastasis. Neuro-Oncology 2022, 25: 1123-1131. PMID: 36472389, PMCID: PMC10237411, DOI: 10.1093/neuonc/noac262.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyStereotactic radiosurgeryBrain metastasesRadiation therapyNeurocognitive declineSerum levelsRadiation-induced neurocognitive declinePretreatment serum markersLow serum levelsAssociated with neurocognitive impairmentRandomized clinical trialsEnzyme-linked immunosorbent assaySurgical resectionSecondary endpointsSerum markersRetrospective analysisClinical trialsNeurocognitive impairmentCognitive impairmentMetastasisBlood samplesImmunosorbent assayMonthsSecondary analysisTherapyImmunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy
Lu Y, Huntoon K, Lee D, Wang Y, Ha J, Qie Y, Li X, Schrank B, Dong S, Gallup T, Kang M, Zhao H, An Y, Yang Z, Li J, Kim B, Jiang W. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy. Nature Nanotechnology 2022, 17: 1332-1341. PMID: 36357792, PMCID: PMC10036139, DOI: 10.1038/s41565-022-01245-7.Peer-Reviewed Original ResearchConceptsInnate immune cellsSolid tumorsImmune cellsEffectiveness of immunotherapyImmune checkpoint blockadeCancer cellsImmune regulatory moleculesHigh response rateCyclic guanosine monophosphate-adenosine monophosphate synthaseBlood cancer cellsInterferon genes (STING) pathwayCheckpoint blockadeCancer immunotherapyHaematological malignanciesImmunotherapyResponse rateTumorsBiological disparitiesLimited responseMember 7Haematologic tumoursDifferential expressionCellsRegulatory moleculesGene pathways
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatients245 Factors associated with in-hospital mortality in mycosis fungoides patients
King A, Lee V, Mirza F, Jairam V, Yu J, Park H, Girardi M, Wilson L, An Y. 245 Factors associated with in-hospital mortality in mycosis fungoides patients. Journal Of Investigative Dermatology 2021, 141: s44. DOI: 10.1016/j.jid.2021.02.267.Peer-Reviewed Original ResearchStrong association of glaucoma with atherosclerosis
Song X, Li P, Li Y, Yan X, Yuan L, Zhao C, An Y, Chang X. Strong association of glaucoma with atherosclerosis. Scientific Reports 2021, 11: 8792. PMID: 33888852, PMCID: PMC8062555, DOI: 10.1038/s41598-021-88322-4.Peer-Reviewed Original ResearchConceptsAqueous humor secretionPrimary diagnosisHumor secretionAS prevalencePrimary diagnosis of glaucomaPrimary diagnosis of hypertensionAngle-closure glaucomaHigh intraocular pressureAssociation of glaucomaDiagnosis of glaucomaEffects of methazolamideLow-density lipoprotein (LDLDiagnosis of hypertensionReduce low-density lipoprotein (LDLGlaucoma prevalenceIntraocular pressureLipoprotein (LDLGlaucoma pathogenesisOphthalmic recordsTreat glaucomaAS patientsGlaucomaOphthalmic diseasesMouse modelIncidence of A
Clinical Trials
Current Trials
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RolePrincipal InvestigatorPrimary Completion Date12/31/2033Recruiting ParticipantsPhase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
HIC ID2000027702RoleSub InvestigatorPrimary Completion Date10/01/2025Recruiting ParticipantsMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
HIC ID2000027403RoleSub InvestigatorPrimary Completion Date11/15/2025Recruiting ParticipantsA Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
HIC ID2000030031RoleSub InvestigatorPrimary Completion Date05/01/2028Recruiting ParticipantsPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
HIC ID2000025868RoleSub InvestigatorPrimary Completion Date01/31/2030Recruiting Participants
Clinical Care
Overview
Yi An, MD, is a radiation oncologist in the Department of Therapeutic Radiology at Yale Medicine. He specializes in treating head and neck, gastrointestinal, prostate and lung cancers.
“I am so fortunate to have the privilege of taking care of cancer patients,”
Dr. An says. “Every day, I have the special opportunity to get to know and form lasting relationships with my patients.” Dr. An is trained in modern radiation treatment techniques, including intensity-modulated radiation therapy, stereotactic body radiation therapy and stereotactic radiosurgery. These cutting-edge radiation techniques, Dr. An says, can target and destroy cancer cells while also minimizing radiation doses to normal tissue and reduce the risk of side effects of treatment.
“Being with my patients at perhaps their most trying time in life,” he says, “drives me to do everything possible to cure their disease and alleviate their pain.”
At Yale School of Medicine, Dr. An is an assistant professor of therapeutic radiology.
Clinical Specialties
Prostate & Genitourinary Radiotherapy; Urologic Oncology; Neuro-Oncology
Fact Sheets
Metastatic Brain Tumors
Learn More on Yale MedicinePrimary Brain Tumors
Learn More on Yale MedicineRadiation Therapy
Learn More on Yale MedicineGerm Cell Tumors
Learn More on Yale Medicine
Board Certifications
Radiation Oncology
- Certification Organization
- AB of Radiology
- Original Certification Date
- 2019